Healthcare Executive and Strategy Consultant
Brings Considerable Innovation, Commercialization and
Entrepreneurial Expertise
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company
developing MultiStem® (invimestrocel) for critical care
indications, announced today the appointment of Neema Mayhugh, PhD
to its Board of Directors. Dr. Mayhugh is an executive with more
than 20 years of experience in healthcare consulting, industry,
academic and hospital settings.
Dr. Mayhugh currently serves as the Founder and Managing Partner
of Wave Strategy, a consultancy focused on the rapid
commercialization of healthcare innovations. Under her leadership,
Wave Strategy has bridged early-stage technologies from renowned
medical institutions with investors and industry experts,
propelling them into the market. Notable partnerships include
collaborations with Mass General Brigham, The Cleveland Clinic and
BioEnterprise Corporation, among others.
Prior to Wave Strategy, Dr. Mayhugh served as Chief Operating
Officer at Mobile Hyperbaric Centers, where she instituted
transformative changes that increased patient volumes and
compliance rates while enhancing organizational efficiency. Earlier
in her career, she held leadership positions at The Cleveland
Clinic and Pfizer, with a focus on commercialization and market
analytics.
“Dr. Mayhugh's appointment to our Board signifies a strategic
step toward enriching our governance with dynamic visionaries. Her
vast experience and achievements in healthcare innovation will
provide valuable insight as we pursue our growth objectives
including advancing our product pipeline in multiple indications,
forging impactful partnerships and licensing our IP portfolio,”
said Ismael Kola, PhD, Chairman of the Athersys Board of
Directors.
“We welcome Dr. Mayhugh’s expertise in commercialization
strategies, portfolio prioritization and deal execution to
Athersys. With multiple late-stage programs, including our most
advanced Phase 3 MASTERS-2 trial evaluating MultiStem in treating
ischemic stroke, her background and current work at Wave Strategy
play a strategic role in adding to the capabilities of our Board as
we progress towards completing our pivotal study,” added Dan
Camardo, Chief Executive Officer of Athersys.
“I am honored to join the Board of Directors at Athersys. A
hallmark of my career has been fostering innovation and driving the
commercialization of groundbreaking healthcare technologies. The
potential of Athersys' MultiStem technology not only resonates with
my passion for creating revolutionary solutions in medicine, but
also offers a promising avenue for addressing a number of
challenging unmet medical needs,” said Dr. Mayhugh.
Beyond her professional endeavors, Dr. Mayhugh is devoted to
community service and is actively involved in the Fostering Hope
Program and the Lawrence School. She is also on the Foundation
Fighting Blindness Innovation Council and is a reviewer for IBD
Ventures, the venture arm of the Crohn’s and Colitis Foundation.
She previously served on the United Way Women's Leadership Council,
as a Director of Open Doors Academy and as a Subcommittee Member of
Prevent Blindness Vision Research.
She holds a PhD in Pharmacology & Toxicology from Dartmouth
College and a BSc in Human Physiology from Boston University.
About MultiStem®
MultiStem® (invimestrocel) cell therapy is a patented
regenerative medicine product in clinical development that has
shown the ability to promote tissue repair and healing in a variety
of ways, such as through the production of therapeutic factors in
response to signals of inflammation and tissue damage. MultiStem
therapy’s potential for multidimensional therapeutic impact
distinguishes it from traditional biopharmaceutical therapies
focused on a single mechanism of benefit. The therapy represents a
unique "off-the-shelf" stem cell product that can be manufactured
in a scalable manner, may be stored for years in frozen form, and
is administered without tissue matching or the need for immune
suppression. Based upon its efficacy profile, its novel mechanisms
of action, and a favorable and consistent tolerability demonstrated
in clinical studies, we believe that MultiStem therapy could
provide a meaningful benefit to patients, including those suffering
from serious diseases and conditions with unmet medical need.
About Athersys
Athersys is a biotechnology company engaged in the discovery and
development of therapeutic product candidates designed to extend
and enhance the quality of human life. The Company is developing
its MultiStem® cell therapy product, a patented, adult-derived
“off-the-shelf” stem cell product, initially for disease
indications in the neurological, inflammatory and immune, and other
critical care indications and has several ongoing clinical trials
evaluating this potential regenerative medicine product. Athersys
has forged strategic partnerships and a broad network of
collaborations to further advance MultiStem cell therapy toward
commercialization. Investors and others should note that we may
post information about the Company on our website at
www.athersys.com and/or on our accounts on Twitter, Facebook,
LinkedIn or other social media platforms. It is possible that the
postings could include information deemed to be material
information. Therefore, we encourage investors, the media and
others interested in the Company to review the information we post
on our website at www.athersys.com and on our social media
accounts. Follow Athersys on Twitter at www.twitter.com/athersys.
Information that we may post about the Company on our website
and/or on our accounts on Twitter, Facebook, LinkedIn or other
social media platforms may contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainties. You should not place
undue reliance on forward-looking statements contained on our
website and/or on our accounts on Twitter, Facebook, LinkedIn or
other social media platforms, and we undertake no obligation to
publicly update forward-looking statements, whether as a result of
new information, future events or otherwise.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. These forward-looking
statements relate to, among other things, the expected timetable
for development of our product candidates, our growth strategy, and
our future financial performance, including our operations,
economic performance, financial condition, prospects, and other
future events. We have attempted to identify forward-looking
statements by using such words as “anticipates,” “believes,” “can,”
“continue,” “could,” “estimates,” “expects,” “intends,” “may,”
“plans,” “potential,” “should,” “suggest,” “will,” or other similar
expressions. These forward-looking statements are only predictions
and are largely based on our current expectations. In addition, a
number of known and unknown risks, uncertainties, and other factors
could affect the accuracy of these statements. Some of the more
significant known risks that we face are the risk that we will be
unable to raise capital to fund our operations in the near term and
long term, including our ability to obtain funding through public
or private equity offerings, debt financings, collaborations and
licensing arrangements or other sources, on terms acceptable to us
or at all, and to continue as a going concern. The following risks
and uncertainties may cause our actual results, levels of activity,
performance, or achievements to differ materially from any future
results, levels of activity, performance, or achievements expressed
or implied by these forward-looking statements: our ability to
raise capital to fund our operations in the near term and long
term, including our ability to obtain funding through public or
private equity offerings, debt financings, collaborations and
licensing arrangements or other sources, on terms acceptable to us
or at all, and to continue as a going concern; whether we receive a
grant from BARDA; our collaborators’ ability and willingness to
continue to fulfill their obligations under the terms of our
collaboration agreements and generate sales related to our
technologies; the possibility of unfavorable results from ongoing
and additional clinical trials involving MultiStem; the risk that
positive results in a clinical trial may not be replicated in
subsequent or confirmatory trials or success in an early stage
clinical trial may not be predictive of results in later stage or
large scale clinical trials; our ability to successfully license
our SIFU technology; our ability to regain and maintain compliance
with the Nasdaq continued listing requirements; the timing and
nature of results from MultiStem clinical trials, including the
MASTERS-2 Phase 3 clinical trial evaluating the administration of
MultiStem for the treatment of ischemic stroke; our ability to meet
milestones and earn royalties under our collaboration agreements,
including the success of our collaboration with Healios; the
success of our MACOVIA clinical trial evaluating the administration
of MultiStem for the treatment of ARDS induced by COVID-19 and
other pathogens, and the MATRICS-1 clinical trial being conducted
with The University of Texas Health Science Center at Houston
evaluating the treatment of patients with serious traumatic
injuries; the availability of product sufficient to meet our
clinical needs and potential commercial demand following any
approval; the possibility of delays in, adverse results of, and
excessive costs of the development process; our ability to
successfully initiate and complete clinical trials of our product
candidates; the possibility of delays, work stoppages or
interruptions in manufacturing by third parties or us, such as due
to material supply constraints, contamination, operational
restrictions due to COVID-19 or other public health emergencies,
labor constraints, regulatory issues or other factors that could
negatively impact our trials and the trials of our collaborators;
uncertainty regarding market acceptance of our product candidates
and our ability to generate revenues, including MultiStem cell
therapy for neurological, inflammatory and immune, cardiovascular
and other critical care indications; changes in external market
factors; changes in our industry’s overall performance; changes in
our business strategy; our ability to protect and defend our
intellectual property and related business operations, including
the successful prosecution of our patent applications and
enforcement of our patent rights, and operate our business in an
environment of rapid technology and intellectual property
development; our possible inability to realize commercially
valuable discoveries in our collaborations with pharmaceutical and
other biotechnology companies; the success of our efforts to enter
into new strategic partnerships and advance our programs; our
possible inability to execute our strategy due to changes in our
industry or the economy generally; changes in productivity and
reliability of suppliers; the success of our competitors and the
emergence of new competitors; and the risks mentioned elsewhere in
our Annual Report on Form 10-K for the year ended December 31, 2022
under Item 1A, “Risk Factors” and our other lings with the SEC. You
should not place undue reliance on forward-looking statements, and
we undertake no obligation to publicly update forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230811432122/en/
Athersys Ellen Gurley Manager of Corporate Communications
and Investor Relations ir@athersys.com
LHA Investor Relations Tirth T. Patel 212-201-6614
Athersys (NASDAQ:ATHX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Athersys (NASDAQ:ATHX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024